FEMY - CIK 0001339005
FEMASYS INC trades as FEMY. In its fiscal 2025 annual report the company posted revenue of $2.29M, up 40.8% from the prior year and net income of -$18.63M. This page tracks FEMASYS INC through 312 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years FEMASYS INC's revenue grew from $1.04M to $2.29M, a compound annual growth rate of 17.2%. Net profit margin compressed from -666.2% to -812.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-08 |
| Major company event | 8-K | 2026-05-08 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| Major company event | 8-K | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-06 |
The largest companies sharing FEMASYS INC's SEC industry classification (surgical & medical instruments & apparatus).
FEMASYS INC reported revenue of $2.29M for fiscal year 2025, an increase of 40.8% year over year.
In its latest fiscal year FEMASYS INC reported a net loss of $18.63M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.